/KMSTF

KMSTF Stock - Kadimastem Ltd

Q: What is the analyst price target for KMSTF?

Analyst price target information is not currently available for KMSTF.

Q: What is KMSTF's market cap?

Market capitalization information is not currently available for KMSTF.

Healthcare|Biotechnology|OTC

$3.21-3.02%

$0.10 (-3.02%) • Nov 20

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $3.53

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for KMSTF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.57

52W High$9.07

52W Low$0.64

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-419,634	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-1,812,742	$-11,039,000	$-22,010,000	$-24,298,000	$-20,288,000
Net Income	$-7,287,196	$-12,048,000	$-22,718,000	$-26,275,000	$-21,710,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-1.74	$-3.97	$-9.21	$-119.97	$-166.71

Company Overview

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was founded in 2008 and is based in Ness Ziona, Israel.

Visit Website

Earnings History & Surprises

KMSTF

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$N/A

EPS Surprise History

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2024	Mar 21, 2024	—	—	—	—
Q3 2020	Aug 25, 2020	—	—	—	—
Q3 2020	Aug 4, 2020	—	—	—	—
Q2 2020	Apr 13, 2020	—	—	—	—
Q4 2019	Dec 18, 2019	—	—	—	—
Q3 2019	Aug 29, 2019	—	—	—	—
Q1 2019	Mar 29, 2019	—	—	—	—